Thirteen abstracts, including five late-breaking abstracts, underscore Jazz's ongoing commitment to advancing the understanding and treatment of serious sleep disorders Oral presentation of XYLO study design to assess systolic blood pressure changes in oxybate patients after switching to low-sodium Xywav® DUBLIN, May 30, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from across its sleep medici ...

DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6, 2024 Fireside chat at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Fireside chat at 7:40 a.m. PT / 10:40 a.m. ET / 3:40 p.m. IST Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma compa ...

Core Insights - The FDA has accepted and granted Priority Review for Jazz Pharmaceuticals' zanidatamab, targeting HER2-positive biliary tract cancer, with a PDUFA date set for November 29, 2024 [1][2] - Zanidatamab is positioned to be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer [1][2] Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, including a growing portfolio of cancer treatments [8] - The company is headquartered in Dublin, Ireland, and is committed to innovative research and development across oncology and neuroscience [8] Clinical Development - The BLA submission for zanidatamab is based on Phase 2b HERIZON-BTC-01 trial results, which showed a confirmed objective response rate of 41.3% in previously treated patients [2][4] - Ongoing Phase 3 HERIZON-BTC-302 trial aims to evaluate zanidatamab's efficacy and safety in combination with standard-of-care therapy for first-line advanced or metastatic HER2-positive biliary tract cancer [3] Regulatory Designations - Zanidatamab has received Breakthrough Therapy designation from the FDA for previously treated HER2 gene-amplified biliary tract cancers, along with two Fast Track designations [5] - The drug has also been granted Orphan Drug designations by both the FDA and the European Medicines Agency for biliary tract cancer and gastric cancer [5] Disease Context - Biliary tract cancer (BTC) accounts for less than 1% of all adult cancers globally and is associated with a poor prognosis, with approximately 12,000 new HER2+ BTC cases diagnosed annually in the U.S., Europe, and Japan [6]

NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis Pharmaceuticals Interim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a l ...

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – t ...

If the market's dramatic shifts this year leave you discombobulated, you're not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we're all desperately seeking. Amidst the current rally, we've seen stocks rise, plummet and rise again, driving investors toward small-caps, tech and growth stocks. While this has been profitable, it might not be the best long-term move. Cheap blue- chip stocks, on the other han ...

Have you assessed how the international operations of Jazz Pharmaceuticals (JAZZ) performed in the quarter ended March 2024? For this drugmaker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investo ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $2.68 per share in first-quarter 2024, missing the Zacks Consensus Estimate of $4.14. Earnings fell 32% year over year, primarily due to increased operating expenses incurred during the quarter.Total revenues in the reported quarter rose 1% year over year to $902 million, driven by higher oncology product sales, which were partially offset by lower neuroscience revenues. Per management, revenues were impacted by seasonal headwinds from payor reauthor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or 011-353-1-634-7800 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (St ...

Jazz Pharmaceuticals (JAZZ) reported $901.98 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1%. EPS of $2.68 for the same period compares to $3.95 a year ago.The reported revenue represents a surprise of -3.94% over the Zacks Consensus Estimate of $938.99 million. With the consensus EPS estimate being $4.14, the EPS surprise was -35.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...